Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4062 ARTÍCULOS , VIENDO DEL 1171 AL 1185

l-dopa-induced off: Functional overlay in Parkinson disease

Erro R, Bozzetti S, Goffi F, Mariotto S, Tinazzi M.

J Neurol Sci. 2016 Jun 15;365:1-2. doi: 10.1016/j.jns.2016.03.022. Epub 2016 Mar 29.

A Japanese multicenter survey characterizing pain in Parkinson's disease

Kubo S, Hamada S, Maeda T, Uchiyama T, Hashimoto M, Nomoto N, Kano O, Takahashi T, Terashi H, Takahashi T, Hatano T, Hasegawa T, Baba Y, Sengoku R, Watanabe H, Kadowaki T, Inoue M, Kaneko S, Shimura H, Nagayama H.

J Neurol Sci. 2016 Jun 15;365:162-6. doi: 10.1016/j.jns.2016.04.015. Epub 2016 Apr 14.

Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases

Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L.

J Control Release. 2016 Aug 10;235:34-47. doi: 10.1016/j.jconrel.2016.05.044. Epub 2016 May 18.

[Problem solving care models for Parkinson's disease]

Csóka M, Molnár S, Kellős É, Domján G.

Orv Hetil. 2016 May 29;157(22):855-68. doi: 10.1556/650.2016.30479.

Benign tremulous Parkinsonism: a unique entity or another facet of Parkinson's disease?

Deeb W, Hu W, Almeida L, Patterson A, Martinez-Ramirez D, Wagle Shukla A.

Transl Neurodegener. 2016 May 20;5:10. doi: 10.1186/s40035-016-0057-1. eCollection 2016.

Cognitive interventions in Alzheimer's and Parkinson's diseases: emerging mechanisms and role of imaging

Vemuri P, Fields J, Peter J, Klöppel S.

Curr Opin Neurol. 2016 Aug;29(4):405-11. doi: 10.1097/WCO.0000000000000346.

Real-time functional magnetic resonance imaging neurofeedback in motor neurorehabilitation

Linden DE, Turner DL.

Curr Opin Neurol. 2016 Aug;29(4):412-8. doi: 10.1097/WCO.0000000000000340.

Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies

Trenkwalder C, Stocchi F, Poewe W, Dronamraju N, Kenney C, Shah A, von Raison F, Graf A.

Mov Disord. 2016 Jul;31(7):1054-8. doi: 10.1002/mds.26585. Epub 2016 May 23.

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease

Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM, Goetz CG, Trenkwalder C, Rascol O.

Mov Disord. 2016 Sep;31(9):1373-80. doi: 10.1002/mds.26659. Epub 2016 May 23.

Total synthesis, biosynthesis and biological profiles of clavine alkaloids

McCabe SR, Wipf P.

Org Biomol Chem. 2016 Jul 7;14(25):5894-913. doi: 10.1039/c6ob00878j. Epub 2016 May 24.

NAT2 polymorphisms and risk for Parkinson's disease: a systematic review and meta-analysis

Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Agúndez JA.

Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):937-46. doi: 10.1080/17425255.2016.1192127. Epub 2016 Jun 3.

Economic Analysis of Deep Brain Stimulation in Parkinson Disease: Systematic Review of the Literature

Becerra JE, Zorro O, Ruiz-Gaviria R, Castañeda-Cardona C, Otálora-Esteban M, Henao S, Navarrete S, Acevedo JC, Rosselli D.

World Neurosurg. 2016 Sep;93:44-9. doi: 10.1016/j.wneu.2016.05.028. Epub 2016 May 20.

Striatal Hand Deformity in Parkinson Disease

Joseph J, Thomas J.

J Clin Rheumatol. 2016 Jun;22(4):219. doi: 10.1097/RHU.0000000000000422.

Adamantane - A Lead Structure for Drugs in Clinical Practice

Spilovska K, Zemek F, Korabecny J, Nepovimova E, Soukup O, Windisch M, Kuca K.

Curr Med Chem. 2016;23(29):3245-3266. doi: 10.2174/0929867323666160525114026.

Medicinal Plants and Natural Products as Potential Sources for Antiparkinson Drugs

Ríos JL, Onteniente M, Picazo D, Montesinos MC.

Planta Med. 2016 Jul;82(11-12):942-51. doi: 10.1055/s-0042-107081. Epub 2016 May 25.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias